Δημοσίευση στις Nov 2017 στο PubMed: https://pubmed.ncbi.nlm.nih.gov/28939201/?from_term=tsioufis&from_sort=date&from_size=200&from_pos=141
Search in PubMed
Search in NLM Catalog
Add to Search
Combination treatment of hypertension has been introduced almost 50 years ago, because of the marked blood pressure (BP) elevation of recruited patients in the early randomized controlled trials of BP lowering. However, in all subsequent trials combination treatment was per protocol anticipated irrespectively of the initial randomized treatment to ensure either a desirable BP lowering or a comparable level of BP reduction among arms. Beyond clinical trials, combination treatment is mainly used in the clinical practice to reinforce ongoing single-agent treatment to achieve hypertension control. Renin-angiotensin system inhibiting drugs are the cornerstone of combination treatment of hypertension because they have been repeatedly tested in clinical trials in combination with other agents either from the beginning or during the follow-up. Effective BP lowering following combination treatment depends on the activation of complementary pathophysiological pathways but different agents can stimulate a common mode of action more effectively. The rate of adverse events following combination treatment may be reduced because effects of each agents are reciprocally counterbalanced. Nevertheless, aggressive BP lowering independently of the implemented combination is associated with increase of treatment discontinuations. In the management of resistant hypertension, a fourth-line agent used on top of the failing triple (diuretic-based) combination is effective to control hypertension only in 50% of patients. At present, it is questioned whether combination treatment of hypertension should be used alternatively to monotherapy in newly-diagnosed hypertensive patients without marked BP elevation or at low cardiovascular risk. Selection between free and fixed-dose combination treatment should be individualized depending on clinical criteria.
Clinical trials; Combination treatment; Fixed-dose combination; Renin-angiotensin system blockers.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Optimizing the Management of Uncontrolled Hypertension: What do Triple Fixed-Dose Drug Combinations Add?
Curr Vasc Pharmacol. 2017;16(1):61-65. doi: 10.2174/1570161115666170414115301.
Curr Vasc Pharmacol. 2017.
Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
Clin Drug Investig. 2010;30(9):625-41. doi: 10.2165/11538440-000000000-00000.
Clin Drug Investig. 2010.
Management of hypertension with fixed-dose triple-combination treatments.
Ther Adv Cardiovasc Dis. 2013 Oct;7(5):246-59. doi: 10.1177/1753944713498638. Epub 2013 Aug 14.
Ther Adv Cardiovasc Dis. 2013.
[On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge–clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
Ter Arkh. 2013;85(9):35-45.
Ter Arkh. 2013.
Hypertension management: rationale for triple therapy based on mechanisms of action.
Cardiovasc Ther. 2013 Oct;31(5):251-8. doi: 10.1111/1755-5922.12015.
Cardiovasc Ther. 2013.
PubMed Central articles
Effects of Hibiscus Sabdariffa Calyces Aqueous Extract on the Antihypertensive Potency of Captopril in the Two-Kidney-One-Clip Rat Hypertension Model.
Evid Based Complement Alternat Med. 2019 Jul 17;2019:9694212. doi: 10.1155/2019/9694212. eCollection 2019.
Evid Based Complement Alternat Med. 2019.
Free PMC article.
Attenuation of High-Fat Diet-Induced Rat Liver Oxidative Stress and Steatosis by Combined Hydroxytyrosol- (HT-) Eicosapentaenoic Acid Supplementation Mainly Relies on HT.
Oxid Med Cell Longev. 2018 Jul 2;2018:5109503. doi: 10.1155/2018/5109503. eCollection 2018.
Oxid Med Cell Longev. 2018.
Free PMC article.